Clinical trial
A Phase I/II Study of Pembrolizumab (MK-3475) in Japanese Pediatric Participants With Specific Solid Tumors or Lymphomas, or in Japanese Adult Participants With Advanced Merkel Cell Carcinoma (KEYNOTE-G21)
NCT07302347 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Study of Pembrolizumab (MK-3475) in Japanese Pediatric Participants With Specific Solid Tumors or Lymphomas, or in Japanese Adult Participants With Advanced Merkel Cell Carcinoma (KEYNOTE-G21)
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- June 23, 2026
- Completion date
- December 31, 2029
- Enrollment
- 20 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
carcinoma, merkel cell, lymphoma, malignant neoplasm